Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities

The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of care for good- and intermediate-risk metastatic renal cell carcinoma. Although generally associated with acceptable toxicity, sunitinib exhibits a novel and distinct toxicity profile that requires monitoring...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kollmannsberger, Christian, Bjarnason, Georg, Burnett, Patrick, Creel, Patricia, Davis, Mellar, Dawson, Nancy, Feldman, Darren, George, Suzanne, Hershman, Jerome, Lechner, Thomas, Potter, Amy, Raymond, Eric, Treister, Nathaniel, Wood, Laura, Wu, Shenhong, Bukowski, Ronald
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2011
Materias:
Academia-Pharma Intersect
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228204/
https://ncbi.nlm.nih.gov/pubmed/21490127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0263
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares